# Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

> **NCT03667703** · PHASE4 · COMPLETED · sponsor: **Boston Children's Hospital** · enrollment: 70 (actual)

## Conditions studied

- Congenital Heart Disease
- Upper Gastrointestinal Bleeding
- Stress Ulcer
- Infection

## Interventions

- **DRUG:** Famotidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03667703
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-10
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03667703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03667703, "Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03667703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*